摘要
磷酸肌醇3激酶(PI3K)–蛋白激酶B(PKB/AKT)–哺乳动物雷帕霉素靶蛋白(mTOR)轴是一个关键的信号转导系统,连接致癌基因和多个受体类别,参与许多重要的细胞功能。异常的PI3K信号通路是癌症中最常见的突变途径之一。由于PI3K/AKT/mTOR通路的致癌激活经常与其他信号网络的突变同时发生,且此类抑制剂有一定的耐药性,因此应考虑联合治疗。在这篇综述中,我们强调了PI3K通路知识的最新研究进展,并讨论了未来探索的方向。
The phosphoinositol 3 kinase (PI3K)-protein kinase B (PKB/AKT) mammalian rapamycin target protein (mTOR) axis is a key signal transduction system that connects oncogenes and multiple receptor categories, participating in many important cellular functions. The abnormal PI3K signaling pathway is one of the most common mutation pathways in cancer. Due to the fact that carcinogenic activation of the PI3K/AKT/mTOR pathway often occurs simultaneously with mutations in other signaling networks, and such inhibitors have certain resistance, combination therapy should be considered. In this review, we highlight the latest research progress on PI3K pathway knowledge and discuss future directions for exploration.
出处
《药物化学》
2023年第2期100-107,共8页
Hans Journal of Medicinal Chemistry
